Peer-influenced content. Sources you trust. No registration required. This is HCN.
At the outset of the pandemic, biotechnology company Novavax was one of the frontrunners to bring a vaccine against COVID-19 to market. But nearly two years later, Novavax’s vaccine has yet to appear. In a compelling article, the BMJ details the repeated delays and setbacks that have torpedoed Novavax’s once-promising vaccine candidate and rendered it unnecessary now that other vaccines from Pfizer, Moderna, and AstraZeneca flood the global marketplace.
Allergy & Immunology December 14th 2021
Only 8 of 35 studies could be included in the meta-analysis. Combined, these indicate a 25% risk reduction for physical distancing, 53% for mask-wearing, and 53% for hand washing. The accompanying BMJ editorial explores the possible reasons for the findings and the oddity that so little quality research is available on such an important topic.
Family Medicine/General Practice November 30th 2021
JAMA Network
In this Original Investigation from JAMA, the authors attempt to discover how the landscape of cancer incidences and deaths will change in the next two decades. The findings suggest marked changes in the landscape of cancer incidence and deaths by 2040, emphasizing the importance of cancer screening, early detection, and prevention to guide research, health care, and health policy efforts.
Hematology April 14th 2021